TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of PEP'C-R on Endurance Parameters and Maximal Cardio-respiratory Function Among Sedentary Older Seniors Over 70

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Low physical activity determined using the questionnaire IPAQ in METs (\<3).~* Informed about the results of examinations performed at screening visit.~* Subject able to understand the purpose, procedures and risks of the study and give written informed consent.~Exclusion Criteria:~* Contraindications to perform the cardiac stress test and PEP'C-R (Musculoskeletal limitations, Unstabilized heart Failure with chest pain on exertion under maximal medical therapy, ventricular and supraventricular disorders, Acute coronary syndrome within \<1 month, Unstabilized respiratory failure or oxygen-dependent)~* Abnormality shown at the cardiac stress test : clinical abnormality (chest pain), electric abnormality (found on ECG), abnormal blood pressure, abnormality of the ventilatory system (bronchospasm, hypoxemia,...)~* Cognitive impairment which exclude PEP'C-R training.~* Current Cancer chemotherapy.~* Visual Impairment which exclude PEP'C-R training.~* Presence of fibromyalgia.~* Subject treated with beta-blockers and other negative chronotropic molecules.~* Acute infection at the time of inclusion.~* Dependent patient.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PEP'C-R (Type: EXPERIMENTAL): Subjects will benefit from one preliminary session and 18 sessions of PEP'C-R, (2 sessions per week for 9.5 weeks).
- Control group (Type: ACTIVE_COMPARATOR): Subjects do not participate in the program PEP'C-R and continue their usual activities at home for 9.5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spectroscopy Versus Standard Care in Cervical Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years and older~* Non-pregnant~* Patients with abnormal smears with cervical intraepithelial neoplasia (both low grade squamous intraepithelial lesions and high grade squamous intraepithelial lesions equal to cervical intraepithelial neoplasia 1-3)~Exclusion Criteria:~* Patients who have had cytotoxic chemotherapy within 12-months prior to enrolling in this study, since the chemotherapy often induces change in the cervix.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colposcopy (Type: EXPERIMENTAL): Colposcopy - a direct magnified inspection of cervix
- Colposcopy + Fluorescence Spectroscopy (Type: EXPERIMENTAL): Colposcopy - a direct magnified inspection of cervix + Fluorescence Spectroscopy - electromagnetic spectroscopy which analyzes fluorescence from a sample.
- Colposcopy + LEEP Procedure (Type: EXPERIMENTAL): Colposcopy - a direct magnified inspection of cervix + loop electrosurgical excision procedure (LEEP) - thin, low-voltage electrified wire loop to cuts out cervix abnormal tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Naloxegol Health Outcome Post Authorisation Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient receives a new prescription for naloxegol or a non-PAMORA laxative. (Note: Only non-PAMORA laxatives that are approved/marketed in the European Union at the time naloxegol is authorized are permitted.)~Exclusion Criteria:~1. Patients \<18 years of age on cohort entry date~2. Patients with \<1 year of continuous data available prior to cohort entry date~3. Patients without exposure to current regular opioid use defined by \>30 days of opioid exposure within the 180 days prior to and inclusive of the cohort entry date~4. Patients with evidence of a cancer indicator (diagnosis or treatment) prior to cohort entry date~5. Exposure to PAMORA laxatives, alvimopan, methylnaltrexone, or naloxone + opioid combination (including fixed-dose combinations) prior to cohort entry date

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- naloxegol (Type: None): patients exposed to naloxegol
- non-PAMORA laxative (Type: None): patient exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Duration Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of non-myeloid malignancy~* Baseline hemoglobin value \>= 11 g/dL and \<= 12 g/dL unrelated to transfusion~* Female patients with reproductive potential must have a negative serum pregnancy test at screening. Patients must have signed an informed consent~Exclusion Criteria:~* Uncontrolled hypertension~* History (within 6 months) of uncontrolled cardiac arrhythmias, or history of pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic events (excluding superficial thromboses), or known history of chronic coagulation disorder~* Transfusion within 28 days prior to first dose~* Planned myelosuppressive chemotherapy or radiation during study and no prior chemotherapy within 8 weeks or radiation within 4 weeks of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Application of Oral Mucosal Epithelial Cell Sheets Cultivated on Amino Membrane in Patients Suffering From Corneal Stem Cell Insufficiency or Symblepharon.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patient with bilateral limbal insufficiency~Exclusion Criteria:~* ocular diseases other than limbal insufficiency glaucoma diseases of retina or optic nerve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Finger Imaging to Detect Blood Flow in the Fingertips

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female who can give informed consent~Exclusion Criteria:~* Under the age of 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Ultrasound Imaging of fingertips

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* To qualify for this study, the patient must have relapsed, refractory or previously untreated low-grade (indolent) non-Hodgkin lymphoma of the following subtypes: Follicular center cell lymphoma grade 1, lymphoplasmacytoid lymphoma, small lymphocytic lymphoma, splenic marginal-zone types lymphoma, monocytoid B-cell lymphoma and extranodal mucosa-associated lymphoid tissue (MALT) lymphomas. Final eligibility will be determined by the health professionals conducting this clinical trial.~Exclusion Criteria:~* Patients who have received prior treatment with purine analogs will be excluded from this study. Also, patients whose diagnostic/histologic subtype cannot be confirmed by our institution will not be able to participate in this study. Final eligibility will be determined by the health professionals conducting this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fludarabine and Mitoxantrome followed by GM-CSF and Rituximab (Type: ACTIVE_COMPARATOR): Initial patients (n=9) received fludarabine (25 mg/m2 IV) and mitoxantrone (10 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m2 IV) and cyclophosphamide (250 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8. All patients received dditional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged ≥ 65 years on the day of vaccination~* Informed consent form signed and dated.~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria :~* Participation in another interventional clinical trial investigating a vaccine, drug, medical device, herbal supplement, or a medical procedure in the 4 weeks preceding the trial vaccination or planned participation in another clinical trial investigating a vaccine, drug, medical device, herbal supplement, or a medical procedure during each year of participation in the study trial.~* Vaccination against influenza in the 6 months preceding the trial vaccination.~* Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or a history of a life-threatening reaction to Fluzone vaccine or to a vaccine containing any of the same substances.~* Personal history of Guillain-Barré syndrome.~* Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures.~* Thrombocytopenia, bleeding disorder, or anticoagulation therapy contraindicating intramuscular (IM) vaccination.~* Known or suspected human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C seropositivity.~* Alcohol abuse or drug addiction that could interfere with the subject's ability to comply with trial procedures.~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.~* Bedridden subjects.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Fluzone® High Dose Group (Type: EXPERIMENTAL): None
- Fluzone® Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Physiotherapy and Capsulitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary idiopathic phase 2 capsulitis~* Diagnosis of capsulitis confirmed by shoulder dilatation~* Patients between 18 and 70 years of age~* Exclusion Criteria:~* Secondary capsulitis~* Shoulder pain of other etiology~* Cognitive disorders~* Patients less than 18 years, and more than 70 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Self rehabilitation (Type: ACTIVE_COMPARATOR): Self rehabilitation
- Self rehabilitation plus physiotherapy (Type: EXPERIMENTAL): Self rehabilitation plus physiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids~* Newly diagnosed or without steroid use during last 1 year~* Endoscopic Mayo subscore \>0~Exclusion Criteria:~* Patients with azathioprine or biologics therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Azathioprine (Type: ACTIVE_COMPARATOR): Azathioprine (1.5mg/kg) po for 1 year
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Social security affiliation~* Written informed consent~* Histologically confirmed stage IV (M1a or M1b) non-small-cell lung cancer, including recurrent non-small-cell lung cancer after a period of complete remission~* D-dimer \> 1,500 µg/L~* First line of systemic cancer treatment (chemotherapy, immunotherapy or targeted therapy), or new line of systemic cancer treatment for cancer progression (chemotherapy, immunotherapy or targeted therapy), introduced during the month preceding inclusion or planned within one month after inclusion~* ECOG (Eastern Cooperative Oncology Group) score 0-2~* Life expectancy \>3 months~Exclusion Criteria:~* Hypersensitivity to heparin or to any excipients~* Septic endocarditis~* History of heparin-induced thrombocytopenia~* Ongoing anticoagulant treatment at therapeutic dosage~* VTE at inclusion~* Creatinin clearance \<30 mL/min~* Active bleeding~* Platelet count \< 100 G/L at inclusion~* Severe hepatic insufficiency~* Cancer treated exclusively with supportive care~* Aspirin at daily dosage \> 160 mg~* Pregnancy~* Patient under tutorship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): usual care,
- Experimental (Type: EXPERIMENTAL): tinzaparin sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 75 years~* End-stage heart failure due to ischemic cardiomyopathy that requires mechanical support according to current indications~* Ability to provide informed consent~Exclusion Criteria:~* Not willing to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Stem cells implantation (Type: EXPERIMENTAL): Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of non-psychotic Major depressive disorder~* HAMD-17 score 14 or greater~* Age of 18 or greater and 65 or less~Exclusion Criteria:~* patients with current or past history of diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic disorder NOS~* patients with current psychotic features, eating disorders or obsessive-compulsive disorder~* patients with neurological disorder~* patients with medical condition that could interfere with everyday life activities~* pregnant or lactating women,~* patients with current other DSM-IV TR Axis I diagnosis other than MDD which needs inpatient care~* patients who treated with ECT for current depressive episode~* insufficient information of past treatment for current depressive episode~* patients who posed a serious suicidal risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paroxetine (Type: EXPERIMENTAL): Paroxetine monotherapy
- Escitalopram (Type: ACTIVE_COMPARATOR): Escitalopram monotherapy
- Venlafaxine (Type: ACTIVE_COMPARATOR): Venlafaxine monotherapy
- Paroxetine+Bupropion (Type: ACTIVE_COMPARATOR): None
- Paroxetine+Lamotrigine (Type: ACTIVE_COMPARATOR): None
- Paroxetine+Lithium (Type: ACTIVE_COMPARATOR): None
- escitalopram+mirtazapine (Type: ACTIVE_COMPARATOR): None
- Escitalopram+Aripiprazole (Type: ACTIVE_COMPARATOR): None
- Paroxetine + Venlafaxine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NSCLC stage IIIA-IIIB~* Performance status 0 or 1 (Zubrod or WHO Scale)~Exclusion Criteria:~* Evidence of metastases either in a separate lobe of the lung, or extra thoracic~* Patients with high risk of radiation pneumonitis and or compromised lung function~* Estimated life expectancy of less than 3 months~* Prior chemotherapy for lung cancer~* Prior radiotherapy to the chest~* Prior surgery with curative intent for lung cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zalutumumab 8 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility